Home

EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)

11.73
-1.43 (-10.87%)
NASDAQ · Last Trade: Oct 15th, 5:51 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close13.16
Open13.12
Bid11.59
Ask11.99
Day's Range11.25 - 13.49
52 Week Range3.910 - 14.91
Volume5,785,396
Market Cap410.36M
PE Ratio (TTM)-4.361
EPS (TTM)-2.7
Dividend & YieldN/A (N/A)
1 Month Average Volume1,104,809

Chart

About EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)

Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions. The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology. Read More

News & Press Releases

12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · October 15, 2025
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Studybenzinga.com
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.
Via Benzinga · October 15, 2025
EyePoint (EYPT) Q2 Revenue Drops 44%fool.com
Via The Motley Fool · August 6, 2025
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Marketchartmill.com
EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid financial setbacks.
Via Chartmill · August 6, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
Analyst Expectations For EyePoint Pharmaceuticals's Futurebenzinga.com
Via Benzinga · May 29, 2025
Earnings Scheduled For May 7, 2025benzinga.com
Via Benzinga · May 7, 2025
A Peek at EyePoint Pharmaceuticals's Future Earningsbenzinga.com
Via Benzinga · May 6, 2025
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviewsbenzinga.com
Via Benzinga · March 6, 2025
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticalsbenzinga.com
Via Benzinga · June 17, 2025
Breakout Momentum Plays You May Not Know About
Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.
Via MarketBeat · June 6, 2025
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · May 28, 2025
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 14, 2025
Analyst Ratings For EyePoint Pharmaceuticalsbenzinga.com
Via Benzinga · October 25, 2024
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · August 13, 2024
Earnings Scheduled For March 5, 2025benzinga.com
Via Benzinga · March 5, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · February 18, 2025
These stocks are moving in today's pre-market sessionchartmill.com
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · February 5, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 5, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · October 28, 2024
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Lossbenzinga.com
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.
Via Benzinga · October 28, 2024
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 28, 2024
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 14, 2024
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Via Benzinga · July 12, 2024
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · July 12, 2024